Novavax: The Beaten-Down COVID-19 Darling

Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX’s Matrix-M adjuvant is a core value driver, validated by major partnerships with Sanofi and Pfizer, offering substantial milestone and royalty upside. Revenue is now primarily driven by licensing and royalties, with product sales from Nuvaxovid declining sharply; partnership dependence is a key risk. Despite early-stage pipeline and unprofitability, NVAX trades at lower multiples than sector medians, making current levels attractive given milestone catalysts.

Novavax ( NVAX ) is a biotechnology company that was, during the COVID-19 time period, valued at over $19.5 billion; now it trades at just around $1.22 billion with a share price of just $7.46.